Advanced Enzyme Technologies Ltd (ADVENZYMES) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Advanced Enzyme Technologies Ltd on NSE and BSE, with an AI summary of each filing.
Please find enclosed herewith the intimation regarding the audio recording of the conference call held on November 03, 2026.
Audio / Video · 04 Nov 2026, 2:09 am
Advanced Enzyme Technologies Releases Q2 FY27 Earnings Call Audio Recording Advanced Enzyme Technologies has made available the audio recording of its investor conference call held on 3rd Nov'26. The call discussed the company's unaudited financial results for the quarter and half-year ended 30th Sep'26. The audio is accessible on the company's website under the analyst corner, with the written transcript set to be submitted to stock exchanges and uploaded in due course pursuant to SEBI LODR regulations.
Intimation for submission of application to Stock Exchanges for Reclassification from Promoter Group to Public Category pursuant to Regulation 31A of the Securities and Exchange Board of ....
Others (Uncategorized) · 03 Nov 2026, 11:08 pm
Advanced Enzyme Technologies Applies for Promoter Group Shareholder Reclassification Advanced Enzyme Technologies submitted applications to BSE and NSE on 3rd Nov'26 to reclassify 13 promoter group entities and individuals to the public category under Regulation 31A of SEBI LODR Regulations. The members seeking reclassification include Savita Chandrakumar Rathi, Piyush Chandrakumar Rathi, Advenza Global Limited, and Snehal Shamsunder Soni, among others. In aggregate, these 13 members hold 59,000 equity shares, representing 0.05% of the company's total shareholding, with several entities holding nil shares.
Please find enclosed herewith Post Buyback Public Announcement.
Others (Uncategorized) · 31 Oct 2026, 9:22 pm
Advanced Enzyme Technologies Concludes Open Market Share Buyback Advanced Enzyme Technologies closed its open market buyback on 30th Oct'26, purchasing 2,410,906 equity shares (2.15% of pre-buyback equity) at an average price of ₹289.09 per share (high: ₹309.05, low: ₹248.30). The company deployed ₹696.96mn, utilizing 99.99% of its maximum buyback size. Post-buyback, total paid-up equity stands reduced to ₹219.13mn (109,565,244 shares) after full extinguishment. Promoter and promoter group holding increased from 43.24% to 44.19%, while public shareholding decreased from 56.76% to 55.81%. The remaining 697,582 shares will be extinguished by 11th Nov'26.
Please find enclosed herewith Earnings Presentation for quarter and half year ended September 30, 2026.
Investor Presentation · 31 Oct 2026, 9:18 pm
Advanced Enzyme Technologies Reports Strong Q2 FY27 Performance Driven by Bio-Processing Growth Advanced Enzyme Technologies reported consolidated revenue from operations of ₹2,145 mn for Q2 FY27, up 16% YoY and 12% QoQ, while H1 FY27 revenue rose 10% YoY to ₹4,062 mn. Q2 FY27 EBITDA grew 20% YoY (36% QoQ) to ₹721 mn with a 34% margin, and PAT increased 14% YoY (33% QoQ) to ₹512 mn (24% margin). Growth was led by Industrial Bio-processing (+43% YoY to ₹365 mn) and Animal Nutrition (+37% YoY to ₹265 mn). India contributed 52% of Q2 revenue (+25% YoY).
Please find enclosed herewith press release titled Quarterly Earnings Release dated October 31, 2026.
Press Release · 31 Oct 2026, 9:10 pm
Advanced Enzyme Technologies Reports Q2 FY27 Results with 14% PAT Growth Advanced Enzyme Technologies reported a 16% YoY increase in consolidated revenue to ₹2,145 million for Q2 FY27 (up 12% QoQ). EBITDA rose 20% YoY to ₹721 million, expanding margins to 34% from 33% in Q2 FY26. Consolidated PAT grew 14% YoY to ₹512 million, maintaining a 24% net margin with EPS at ₹4.33. Revenue expansion was led by Bio-Processing (up 43% YoY to ₹365 million) and Animal Nutrition (up 37% YoY to ₹265 million). Domestic revenue increased 25% YoY to ₹1,110 million, contributing 52% of total sales.
The Board of Directors at their meeting held today i.e. October 31, 2026 have analysed the request received from the Promoter Group members for their reclassification from promoter group ....
Others (Uncategorized) · 31 Oct 2026, 9:06 pm
Advanced Enzyme Technologies Reports Q2 Results and Evaluates Promoter Reclassification Requests Advanced Enzyme Technologies reported consolidated revenue from operations of ₹2,145.09 million for the quarter ended 30th Sep'26, up 16.25% YoY from ₹1,845.28 million, with net profit rising 14.35% YoY to ₹511.53 million. Separately, the board analyzed promoter reclassification requests on 31st Oct'26: requests from Promoter Group I were deemed non-compliant due to related persons exceeding the 10% voting rights threshold (holding 28.23%), while requests from eight Promoter Group II members holding 0.05% collectively met SEBI norms and will proceed for exchange approvals.
Advanced enzyme Technologies Limited has informed the exchange about the unaudited financial results (Standalone and Consolidated) of the Company for the quarter and half year ended September ....
Financial Result · 31 Oct 2026, 6:45 pm
With reference to the notice of the Board Meeting dated October 23, 2026, we hereby inform that the Board of Directors at its meeting held on October 31, 2026 has approved the Unaudited ....
Outcome · 31 Oct 2026, 6:36 pm
The Board of Directors at their meeting held today i.e. October 31, 2026 have analyzed the requests received from the promoter group members for their reclassification from promoter group category to public category shareholders, pursuant to Regulation 31A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended
Outcome · 31 Oct 2026, 6:22 pm
Advanced Enzyme Technologies Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 31 Oct 2026, 6:16 pm
Advanced Enzyme Technologies Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) ■ Revenue: 2,145 (+16.2% YoY | +11.9% QoQ) ■ EBITDA: 721 (+20.1% YoY | +36.4% QoQ) ■ EBITDA Margin (%): 33.6 (+107 bps YoY | +603 bps QoQ) ■ PAT: 483 (+11.5% YoY | +30.2% QoQ) ■ EPS (INR): 4.32 (+11.6% YoY | +30.5% QoQ)
Closure of Buyback
Others (Uncategorized) · 31 Oct 2026, 12:45 am
Advanced Enzyme Technologies Concludes Open-Market Share Buyback Advanced Enzyme Technologies announced the closure of its open-market buyback on 30th Oct'26, successfully utilizing ₹696.96m, or 99.99% of the ₹697.00m maximum authorized size. Commenced on 14th Aug'26, the company repurchased 2,410,906 equity shares at an average price of ₹289.09 per share, below the ceiling price of ₹500.00. Following the extinguishment of repurchased shares, total equity capital contracts from 111,976,150 to 109,565,244 shares, raising promoter group holding from 43.24% to 44.19% while public holding adjusts to 55.81%.
Daily Report pursuant to Regulation 18(i) of the Buyback Regulations regarding the Equity Shares bought back on October 30, 2026
Others (Uncategorized) · 31 Oct 2026, 12:07 am
Advanced Enzyme Technologies Reports Nil Share Purchases in Daily Buyback Update Advanced Enzyme Technologies reported nil equity shares bought back on 30th Oct'26 across BSE and NSE under its ongoing open-market share buyback program executed through Emkay Global Financial Services. The company's cumulative total of equity shares (face value ₹2 each) repurchased under the buyback remains unchanged at 24,10,906 shares as of 30th Oct'26, with zero quantities closed out to date.
Daily Report pursuant to Regulation 18(i) of the Buyback Regulations regarding the Equity Shares bought back on October 29, 2026
Others (Uncategorized) · 29 Oct 2026, 11:10 pm
Advanced Enzyme Technologies Reports Daily Equity Share Buyback Details Advanced Enzyme Technologies bought back 54,455 equity shares at an average acquisition price of ₹263.7616 per share via the NSE on 29th Oct'26, executed through Emkay Global Financial Services. Following this transaction, the company's cumulative total of equity shares repurchased under the ongoing open-market buyback program reached 24,10,906 shares. No shares were bought back on the BSE or closed out during the period.
Daily Report pursuant to Regulations 18(i) of the Buyback Regulations regarding the Equity Shares bought back on October 28, 2026
Others (Uncategorized) · 28 Oct 2026, 11:42 pm
Advanced Enzyme Technologies Reports Daily Equity Share Buyback Details Advanced Enzyme Technologies bought back 64,583 equity shares (face value ₹2 each) on 28th Oct'26 via NSE at an average price of ₹262.4914 per share, excluding transaction costs. Zero shares were acquired via BSE. With this transaction, the company's cumulative equity shares bought back reached 23,56,451 shares, up from 22,91,868 shares prior to the trade date, with no closed-out quantities recorded.
Daily Report pursuant to Regulation 18(i) of the Buyback Regulations regarding the Equity Shares bought back on October 27, 2026
Others (Uncategorized) · 27 Oct 2026, 11:32 pm
Advanced Enzyme Technologies Reports Daily Share Buyback Update Advanced Enzyme Technologies bought back 29,115 equity shares (face value ₹2 each) on 27th Oct'26 through Emkay Global Financial Services at an average acquisition price of ₹256.4868 per share via open market on the NSE. With zero shares purchased on BSE and no close-out quantities, cumulative equity shares bought back under the program reached 22,91,868 shares as of 27th Oct'26, up from 22,62,753 shares prior to the transaction.
Conference call for Analysts and Investors to discuss the un-audited financial results of the Company for the quarter and half year ended September 30, 2026 on Tuesday, November 03, 2026 ....
Intimation · 03 Nov 2026, 4:00 pm
Advanced Enzyme Technologies Schedules Q2 and H1 FY27 Earnings Call Advanced Enzyme Technologies Limited will host an earnings conference call for analysts and investors on 3rd Nov'26 at 16:00 IST to discuss its un-audited financial results for the quarter and half-year ended 30th Sep'26. The management team will be represented by Whole-time Director Mukund Kabra and Chief Financial Officer Beni Prasad Rauka. Primary dial-in numbers for the call are +91 22 6280 1403 and +91 22 7115 8304, alongside international toll-free access for key global regions.
Daily Report pursuant to Regulation 18(i) of the Buyback Regulations regarding the Equity Shares bought back on October 26, 2026
Others (Uncategorized) · 26 Oct 2026, 11:42 pm
Advanced Enzyme Technologies Reports Daily Share Buyback Update Advanced Enzyme Technologies bought back 61,900 equity shares (face value ₹2 each) from the open market via NSE on 26th Oct'26 at an average price of ₹251.2710 per share, excluding transaction costs. No shares were purchased on BSE. The transaction was executed via Emkay Global Financial Services. Following this acquisition, the company's cumulative total of equity shares bought back under the ongoing program reached 22,62,753 shares, up from 22,00,853 shares as of the previous trading day, with zero closed-out quantities reported.
Daily Report pursuant to Regulation 18(i) of the Buyback Regulations regarding the Equity Shares bought back on October 23, 2026
Others (Uncategorized) · 23 Oct 2026, 10:40 pm
Advanced Enzyme Technologies Reports Daily Buyback Status for October 2026 Advanced Enzyme Technologies reported nil equity share purchases via the open market mechanism on 23rd Oct'26 through broker Emkay Global Financial Services. The company's cumulative equity shares bought back under the ongoing program stood unchanged at 22,00,853 shares of ₹2 face value as of 23rd Oct'26, with zero quantity closed out.
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 31 Oct 2026, 5:30 am
Advanced Enzyme Technologies Limited has informed the Exchange about Board Meeting to be held on 31-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 31 Oct 2026, 5:30 am
Advanced Enzyme Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/10/2026 ,inter alia, to consider and approve the Un-Audited ....
Intimation · 31 Oct 2026, 5:30 am
Advanced Enzyme Technologies Schedules Board Meeting to Approve Q2 Results Advanced Enzyme Technologies Limited announced that its Board of Directors is scheduled to meet on 31st Oct'26 to consider and approve the unaudited standalone and consolidated financial results for the quarter and half-year ended 30th Sep'26. In connection with the results announcement, the trading window for dealing in the company's securities will remain closed until 2nd Nov'26.
Daily Report pursuant to Regulation 18(i) of the Buyback Regulations regarding the Equity Shares bought back on October 22, 2026
Others (Uncategorized) · 22 Oct 2026, 11:12 pm
Advanced Enzyme Technologies Reports Daily Share Buyback Update for 22nd Oct'26 Advanced Enzyme Technologies Limited bought back 58,326 equity shares (face value ₹2 each) from the open market via NSE on 22nd Oct'26 at an average acquisition price of ₹263.3605 per share (excluding transaction costs). Following this transaction executed through Emkay Global Financial Services Limited, the company's cumulative total of equity shares repurchased reached 22,00,853 shares, up from 21,42,527 shares bought back as of the previous trading day.
Daily Report pursuant to Regulation 18(i) of the Buyback Regulations regarding the Equity Shares bought back on October 21, 2026
Others (Uncategorized) · 21 Oct 2026, 11:46 pm
Advanced Enzyme Technologies Reports Daily Open Market Equity Share Buyback Update Advanced Enzyme Technologies bought back 57,000 equity shares (face value ₹2 each) via the open market on 21st Oct'26 through NSE at an average price of ₹262.7600 per share, executed by Emkay Global Financial Services. No shares were repurchased on BSE. Following this transaction, the company's cumulative equity shares bought back under the current program reached 21,42,527 shares, up from 20,85,527 shares repurchased as of the previous trading day.
Intimation of receipt of request from Promoter Group Member for reclassification from Promoter Group Category to Public Category Shareholders under Regulation 31A of the SEBI (Listing Obligations ....
Others (Uncategorized) · 20 Oct 2026, 10:51 pm
Advanced Enzyme Technologies Receives Promoter Group Reclassification Request Advanced Enzyme Technologies Ltd. received a request on 20th Oct'26 from promoter group member Snehal Shamsunder Soni seeking reclassification to the 'Public' category under Regulation 31A of SEBI LODR Regulations. The shareholder holds 15,000 equity shares, representing a 0.01% stake in the company. The applicant confirmed having no management role, board representation, special rights, or control over company affairs. The proposed reclassification remains subject to necessary approvals from the Board of Directors, stock exchanges, and compliance with statutory regulatory conditions.
Intimation of receipt of request from Promoter Group Member for reclassification from Promoter Group Category to Public Category Shareholders under Regulation 31A of the SEBI (Listing Obligations ....
Others (Uncategorized) · 19 Oct 2026, 10:56 pm
Advanced Enzyme Technologies Receives Promoter Group Reclassification Request Advanced Enzyme Technologies Ltd received a formal request on 19th Oct'26 from promoter group member Pratik Prakash Kokane seeking reclassification to the 'Public' category under Regulation 31A of SEBI LODR Regulations. Kokane currently holds 10,000 equity shares, representing a 0.01% stake in the company. The reclassification request cited lack of management control or special rights and remains subject to approvals from the company's Board of Directors, stock exchanges, and shareholders.